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Pedigrees with HG or IG. Filled symbols represent individuals with IG; half-filled symbols, those with HG. Open symbols represent normal family 
members. An arrow indicates the index case. Pedigrees 1–3 are French-Canadian; pedigrees 4–7 are Australian; pedigree 7 is of Coptic-Egyp-
tian descent. The urine of subject 6.1 was not tested, and subject 5.1 was deceased.
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Mutations and polymorphisms identified in SLC36A2 and SLC6 amino acid transporter (II) family members that contribute to HG and IG
Gene SLC36A2 SLC6A20 SLC6A18 SLC6A19
Locus 5q33.1 3p21.3 5p13.33 5p13.33
Allele  260G→T IVS1+1G→A 596C→T 235G→A 957C→G 1433T→C 1486G→A IVS7–4G→A
Mutation/SNP  G87V IVS1+1G→A T199M G79S Y319X L478P G496R IVS7–4G→A
Frequency  0.012 0.004 0.075 ND 0.441 0.386 0.003 0.22
RefSNP ID    rs17279437  rs7447815 rs4073918  rs35329108
Subject Phenotype
1.1 NM +/– +/+ +/+ +/+ +/+ +/– +/+ –/–
1.2 HG +/– +/+ +/– +/+ +/– +/+ +/+ +/–
1.3 IG –/– +/+ +/– +/+ +/– +/– +/+ +/–
1.4 IG –/– +/+ +/– +/+ +/– +/– +/+ +/–
2.1 HG –/– +/+ +/+ +/+ +/+ –/– +/+ +/+
2.2 HG +/– +/+ +/– +/+ +/– +/– +/+ +/+
2.3 IG –/– +/+ +/– +/+ +/+ –/– +/+ +/+
2.4 IG –/– +/+ +/– +/+ +/+ –/– +/+ +/+
3.1 HG +/– +/+ +/– +/+ +/+ +/– +/+ +/+
3.2 HG +/– +/+ +/+ +/+ +/–A +/–A +/+ +/+
3.3 IG –/– +/+ +/– +/+ +/+ –/– +/+ +/+
4.1 HG +/– +/+ +/+ +/+ +/+ +/+ +/+ +/–
4.2 HG +/– +/+ +/– +/+ +/– +/+ +/+ +/–
4.3 NM +/+ +/+ +/– +/+ +/+ +/+ +/+ +/–
4.4 IG –/– +/+ +/+ +/+ +/+ +/+ +/+ –/–
5.1 DEC N/A N/A N/A N/A N/A N/A N/A N/A
5.2 NM +/+ +/+ +/+ +/+ –/– +/+ +/+ +/+
5.3 HG +/– +/+ +/– +/– +/– +/+ +/+ +/–
5.4 NM +/+ +/+ +/+ +/+ +/– +/+ +/+ +/+
6.1 N/A N/A N/A N/A N/A N/A N/A N/A N/A
6.2 HG +/+ +/+ –/– +/+ +/– +/+ +/+ +/–
6.3 NM +/+ +/+ +/+ +/+ +/– +/+ +/+ +/+
6.4 HG +/+ +/+ +/– +/+ +/– +/– +/+ +/–
7.1 HG +/+ +/– +/+ +/+ +/+ +/+ +/– –/–
7.2 HG +/+ +/– +/+ +/+ +/– +/+ +/+ +/–
7.3 NM +/+ +/+ +/+ +/+ +/+ +/+ +/+ –/–
7.4 HG +/+ +/– +/+ +/+ +/+ +/+ +/– –/–
7.5 HG +/+ +/– +/+ +/+ +/– +/+ +/– +/–
7.6 IG +/+ –/– +/+ +/+ +/– +/+ +/– +/–
Each subject is listed with phenotype: IG, HG, and normal (NM); and with genotype from the 4 candidate genes SLC36A2 (RefSeq NM_181776.1), 
SLC6A20 (NM_022405.2), SLC6A18 (NM_182632.1), and SLC6A19 (NM_001003841). N/A, not available; ND, not determined; DEC, deceased. AMuta-
tions on the same allele. All SLC6A18 mutations/SNPs were compound heterozygous unless otherwise indicated. RefSNPs are shown with identifiers and 
frequencies where known; frequencies of novel mutations were calculated in a panel of healthy individuals.
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Mutations identified in IG and HG candidate genes SLC36A2, SLC6A20, and SLC6A18 encode highly conserved amino acid residues in trans-
membrane regions. Multiple amino acid sequence alignments were performed using ClustalW. Human RefSeq protein SLC36A2 (NP_861441.1) 
was aligned with SLC36A1 (NP_510968.2), SLC36A3 (NP_861439.2), and SLC36A4 (NP_689526.2). SLC6A20 (NP_064593.1) and SLC6A18 
(NP_872438.1) were aligned with members of the SLC6 amino acid transporter (II) family (39): SLC6A15 (NP_877499.1); SLC6A16 (NP_054756.2); 
SLC6A17 (NP_001010898.1); and SLC6A19 (NP_001003841.1). Orthologs from other species were sourced from Ensembl release 47. Gray shad-
ing indicates residues that are conserved in the majority of sequences. Mutations identified in this study are indicated with arrows: (A) SLC36A2 
G87V; mutation is in the second transmembrane helix; (B) SLC6A20 T199M; mutation is in the fifth transmembrane helix; (C) SLC6A18 G79S; 
mutation is in the second transmembrane helix; and (D) SLC6A18 L478P and G496R, both located in the tenth transmembrane helix.
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Location of IG-associated mutations in SLC36A2, 
SLC6A18, and SLC6A20. A topology model suggests 
location of residue G87 at the beginning of helix 2 
(orange, A). Homology models of SLC6A20 (B) and 
SLC6A18 (C) were generated according to the struc-
ture of LeuT (51). Affected residues are indicated and 
shown in van der Waals projection. Both G79 and G496 
are located at or close to critical helical turns, whereas 
L478 is located in the center of helix 10.
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Transport activity of mutant proline 
and glycine transporters. Oocytes 
were injected with WT or mutant 
cRNA encoding the proton amino 
acid transporter SLC36A2, the 
imino acid transporter SLC6A20, 
or the putative glycine transporter 
SLC6A18. (A) After incubation 
for 3 days (SLC36A2 WT and its 
mutant G87V) or 4 days (SLC6A18 
and SLC6A20 WT and its mutant 
T199M), uptake of glycine and 
proline was measured. Each bar 
represents the mean ± SD uptake 
activity of 10 oocytes. The experi-
ment was repeated 3 times, with 
equivalent results. (B) Concentra-
tion dependence of proline-induced 
inward currents (Ipro) induced in 
SLC36A2-expressing oocytes. 
Currents mediated by the G87V 
mutant are shown relative to the 
currents induced in WT transport-
er–expressing oocytes. Each data 
point represents the mean ± SD 
transport activity of n = 7 oocytes. 
(C) Concentration dependence of 
glycine-induced inward currents in 
SLC36A2-expressing oocytes (n = 7 
experiments). Surface expression 
of eGFP-transporter fusions of WT 
(D) and G87V mutant (E) SLC36A2 
in Xenopus laevis oocytes in com-
parison to noninjected oocytes (F).
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Analysis of the SLC36A2 IVS1+1G→A splice donor site mutation using 
a minigene system. The mutation alters the consensus splice donor 
site (AC|gtgagt). Each minigene contained an N-terminal c-myc epit-
ope tag and a C-terminal FLAG tag for detection: (A) WT SLC36A2. 
(B) Minigene with 3,029-bp IVS1 containing the WT IVS1+1G allele. 
(C) Minigene with IVS1 containing the mutant IVS1+1A allele. The 
full-length cDNA is represented as the upper form, and the predicted 
expressed polyadenylated transcript as the lower form; V indicates 
the location of the IVS1+1G→A mutation; the asterisk indicates the 
premature stop codon TGA. The SLC36A2 minigenes or a control 
vector with c-myc–tagged SLC6A20 were transfected into MDCKII 
cells and selected in G418 antibiotic, and RNA was extracted. The 
results of seminested RT-PCR using 5′ primer W and different 3′ 
primers X, Y, or Z designed to qualitatively assess the effect of the 
IVS1+1G→A mutation on splicing: (D) WX, X is within exon 2, (E) 
WY, Y bridges the WT exon 1/exon 2 junction, (F) WZ, Z bridges the 
mutant exon 1/exon 2 junction. Expected product sizes in bp are indi-
cated. Lane 1, SLC36A2 full-length; lane 2, SLC36A2 WT IVS1+1G; 
lane 3, SLC36A2 mutant IVS1+1A; lane 4, SLC6A20 control; lane 5, 
first-round seminested negative control. All products were sequenced, 
and the results confirmed bioinformatic predictions that the 1G→A 
mutation abrogated normal splicing of IVS1, leading to the use of an 
alternative splice donor site (AG|gtgggt) 70 bp downstream. A prema-
ture stop codon within the alternative spliced transcript would truncate 
the protein at 55 amino acid residues.
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Transport activity of mutant SLC6A20. 
Oocytes were injected with WT or mutant 
cRNA encoding the imino acid transporter 
SLC6A20 (25 ng). After incubation for 4 
days, [14C]proline uptake was determined 
in the presence of different concentra-
tions of proline (A) and at a proline con-
centration of 50 μM in the presence of 
different Na+ concentrations (B) or differ-
ent concentrations of Cl– (C). Each data 
point represents the mean ± SD transport 
activity of n = 10 oocytes. Surface expres-
sion of eGFP-transporter fusions of WT 
(D) and mutant T199M (E) SLC6A20 in 
Xenopus laevis oocytes in comparison 
to noninjected oocytes (F). Each experi-
ment was repeated 3 times, with equiva-
lent results.
Figure 
Expression of SLC36A2 and SLC6A20 in adult human kidney. (A) Immunofluorescence of SLC36A2 (green) revealed colocalization (yellow) with 
the proximal tubule marker Lotus teragonolobus agglutinin (LTA; red) on the apical membrane of the S1 segment of proximal tubules. Arrows 
indicate SLC36A2 expression in the S1 segment of a proximal tubule close to the glomerulus (g). (B) Immunofluorescence of SLC6A20 (green) 
revealed colocalization (yellow) with LTA (red) on the apical membrane of the S2-S3 segment of proximal tubules. Arrow indicates SLC6A20 
expression in the S3 segment of a proximal tubule. (C) Colocalization was not observed in sections stained for both SLC36A2 (green) and 
SLC6A20 (red). Negative controls for A, B, and C showed no staining (data not shown). Original magnification, ×40. Scale bars: 30 μm.
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Model of imino acid and glycine reabsorption in 
the kidney. Different transporters in the S1 and 
S2/S3 segments of the proximal tubule mediate 
uptake of imino acids and glycine. In the S1 seg-
ment, the main transporters are SLC36A2 and 
SLC6A19, which both transport imino acids and 
glycine. In the S2/S3 segment, imino acid trans-
port is mediated by SLC6A20, whereas glycine 
transport is mediated by SLC6A18. SLC6A19 
contributes to neutral amino acid (AA0) reab-
sorption throughout the proximal tubule. Para-
cellular transport is an alternate mechanism of 
glycine reabsorption (dashed arrow).
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Prediction of the renal phenotype from the genotype. The results of in vivo urine analysis and in vitro transport 
experiments were combined to estimate the contribution of SLC6A19, SLC6A18, SLC6A20, and SLC36A2 
to proline and glycine reabsorption in the kidney. Reabsorption capacity above 100% would manifest as a 
normal urinary phenotype. The urine phenotype is indicated below the subject as normal (NM), HG, or IG. 
The following formula was used to estimate proline and glycine reabsorption: (activity of allele 1 + activity of 
allele 2)/2 × contribution of SLC36A2 + (activity of allele 1 + activity of allele 2)/2 × contribution of SLC6A18 
+ (activity of allele 1 + activity of allele 2)/2 × contribution of SLC6A19 + (activity of allele 1 + activity of allele 
2)/2 × contribution of SLC6A20. The following contributions to proline transport were used: SLC36A2 (60 
AU); SLC6A18 (0 AU, not a substrate); SLC6A19 (40 AU); SLC6A20 (40 AU). The following contributions to 
glycine transport were used: SLC36A2 (40 AU); SLC6A18 (10 AU); SLC6A19 (60 AU); SLC6A20 (0 AU, not 
a substrate). The activity of individual alleles was calculated as a fraction of 1, reflecting the activity of the 
mutant compared with the WT when expressed in Xenopus laevis oocytes. The algorithm correctly replicates 
the urinary phenotype of 25 of the 28 individuals.
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